InvestorsHub Logo
Followers 67
Posts 7269
Boards Moderated 0
Alias Born 03/06/2016

Re: antihama post# 674374

Saturday, 02/24/2024 10:19:09 AM

Saturday, February 24, 2024 10:19:09 AM

Post# of 692407

"Here's another bit that caught my eye
What your question really goes to is how will international recognition impact on our regulatory role for the future? My hope is that we will certainly retain some of the important innovation pathways where we add value. Let me give you an example in relation to personalized immunotherapies. Because the U.K.’s health ecosystem is joined up, we're able to bring clinicians and health care organization leaders into the regulatory discussions. In this way, we can consider dedicated regulatory pathways for products that have a very short shelf life or products that are tailored to the genomics of a particular cancer or indeed therapies for very rare genetic disorders. These are quite a challenge for regulation, and it's not going to be ‘one size fits all.’ The question is whether we can license platforms as opposed to products. This is a really exciting time in the evolution of regulation, and my ambition is for our voice to be part of that international discussion that is now ongoing."




Yep, I pointed that out two days ago (post # 674104)...Short memory I guess!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News